Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain

Pain Medicine (United States)

Volumn 15, Issue 8, 2014, Pages 1365-1372

  Passik, Steven D ^a   Narayana, Arvind ^b   Yang, Ronghua ^b  

^a Millennium Research Institute   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

Author keywords

Aberrant behavior; Breakthrough pain; Chronic pain; Fentanyl buccal tablet; Opioid; Risk assessment

Indexed keywords

FENTANYL CITRATE; OXYCODONE; DRUG DOSAGE FORM; FENTANYL; NARCOTIC ANALGESIC AGENT; TABLET;

ADDICTION BEHAVIORS CHECKLIST; ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; BEHAVIOR DISORDER; BREAKTHROUGH PAIN; CHECKLIST; CHRONIC PAIN; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOCLONUS; OPEN STUDY; OPIATE THERAPY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCREENER AND OPIOID ASSESSMENT FOR PATIENTS WITH PAIN REVISED; UNITED STATES; VERY ELDERLY; BUCCAL DRUG ADMINISTRATION; DRUG DOSAGE FORM; MIDDLE AGED; OPIOID-RELATED DISORDERS; TABLET;

ADMINISTRATION, BUCCAL; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; CHRONIC PAIN; CROSS-OVER STUDIES; DOSAGE FORMS; DOUBLE-BLIND METHOD; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; OXYCODONE; TABLETS;

EID: 84906085444     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12431     Document Type: Article

References (24)

1. Trescot AM, Boswell MV, Atluri SL, etal. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1-39.
2. Chou R, Fanciullo GJ, Fine PG, etal. for the American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-130.
3. Ballantyne JC. Chronic pain following treatment for cancer: The role of opioids. Oncologist 2003;8:567-575.
4. Ives TJ, Chelminski PR, Hammett-Stabler CA, etal. Predictors of opioid misuse in patients with chronic pain: A prospective cohort study. BMC Health Serv Res 2006;6:46-55.
5. Passik SD. Issues in long-term opioid therapy: Unmet needs, risks, and solutions. Mayo Clin Proc 2009;84:593-601.
6. Compton P, Darakjian J, Miotto K. Screening for addiction in patients with chronic pain and "problematic" substance use: Evaluation of a pilot assessment tool. J Pain Symptom Manage 1998;16:355-363.
7. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Med 2005;6:432-442.
8. Chou R, Fanciullo GJ, Fine PG, etal. Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:131-146.
9. Effentora Buccal Tablets [package insert]. Maisons-Alfort, France: Cephalon Europe; 2011.
10. Fentora [package insert]. Frazer, PA: Cephalon, Inc.; 2011.
11. Webster L, Slevin K, Narayana A, etal. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: A randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med 2013;14:1332-1345.
12. Webster L, Narayana A, Janka L. Functioning/satisfaction with fentanyl buccal tablet compared to traditional short-acting opioids for the management of breakthrough pain in opioid-tolerant patients with chronic pain [abstract 345]. J Pain 2011;12(suppl 4):P62.
13. Marsch LA, Bickel WK, Badger GJ, etal. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 2001;299:1056-1065.
14. Fine PG, Narayana A, Passik SD. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: Appropriate patient selection and management. Pain Med 2010;11:1024-1036.
15. International Conference on Harmonisation Working Group. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Washington, DC; 1996. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf (accessed March 2014).
16. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain 2008;9:360-372.
17. Wu SM, Compton P, Bolus R, etal. The Addiction Behaviors Checklist: Validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage 2006;32:342-351.
18. Butler SF, Budman SH, Fernandez KC, etal. Development and validation of the Current Opioid Misuse Measure. Pain 2007;130:144-156.
19. Michna E, Ross EL, Hynes WL, etal. Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history. J Pain Symptom Manage 2004;28:250-258.
20. Passik SD, Kirsh KL, Whitcomb L, Dickerson PK, Theobald DE. Pain clinicians' rankings of aberrant drug-taking behaviors. J Pain Palliat Care Pharmacother 2002;16:39-49.
21. Portenoy RK. Opioid therapy for chronic nonmalignant pain: A review of the critical issues. J Pain Symptom Manage 1996;11:203-217.
22. Passik SD, Messina J, Golsorkhi A, Xie F. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J Pain Symptom Manage 2011;41:116-125.
23. Bhamb B, Brown D, Hariharan J, etal. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin 2006;22:1859-1865.
24. Passik SD, Kirsh KL. The need to identify predictors of aberrant drug-related behavior and addiction in patients being treated with opioids for pain. Pain Med 2003;4:186-189.